Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.

Also called NCT04013581

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 121 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04013581
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04013581. Randomized; no masking; primary purpose treatment. Start 2019-08-05 (actual); primary completion 2020-05-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
TZD group
Intervention (Drug)
SGLT-2 group
Lead sponsor
Yonsei University (class: other)

Record details

Record id
cardio:ct-nct04013581
Content hash
44ad9fe628e2d3031388305ba4f83029fec4cc726ec697541690a675e8638387